Roivant Sciences Ltd.
ROIV
Rank in Stocks
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Share Price
$33.73
Last synced: 2026-07-31
Market Cap
$24.37B
Change (1 day)
-2.28%
Change (1 year)
90.15%
Country
GB
Trade Roivant Sciences Ltd. (ROIV)
Category
Healthcare
Number of shares outstanding for Roivant Sciences Ltd. (ROIV)
Number of shares outstanding as of June 2026: 720.78M
According to Roivant Sciences Ltd. latest financial reports and stock price the company's current number of shares outstanding is 720.78M. At the end of March 2024 the company had 783.25M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Roivant Sciences Ltd. (ROIV) from 2020 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 720.78M | -0.64% |
| 2025 | 725.40M | -7.39% |
| 2024 | 783.25M | 9.88% |
| 2023 | 712.79M | 6.43% |
| 2022 | 669.75M | -2.20% |
| 2021 | 684.79M | 0.00% |
| 2020 | 684.79M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -64.77% |
US
|
|
| 396.00M | -45.06% |
US
|
|
| 478.91M | -33.56% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -91.37% |
NL
|
